ACPH.BR - Acacia Pharma Group plc

Brussels - Brussels Delayed Price. Currency in EUR
2.2200
-0.0500 (-2.20%)
As of 2:10PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close2.2700
Open2.3500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.2000 - 2.3500
52 Week Range1.2900 - 3.9950
Volume37,942
Avg. Volume406,508
Market Cap142.346M
Beta (5Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-0.4250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est395.38
  • GlobeNewswire

    Publication of Prospectus

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, BY ANY MEANS OR MEDIA IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THIS ANNOUNCEMENT. This announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority and not a prospectus.

  • GlobeNewswire

    Forthcoming 2020 Annual General Meeting – Change of Venue and Proxy Forms

    Cambridge, UK and Indianapolis, US – 23 March 2020 Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (ACPH.NX) notes that further to the Company’s announcement and publication of its notice of meeting convening the Annual General Meeting (“AGM”) on 13 March 2020, the Board has now been advised that, in response to the concerns arising from the Covid-19 (or Coronavirus) pandemic and the UK Government’s latest advice in relation to measures aimed at managing the pandemic, the venue and facilities intended for the AGM will no longer be available on 7 April 2020. The AGM will still proceed on the previously notified date and time, 11.00 a.m. on 7 April 2020, but the Board has determined that the venue for the AGM be changed to The Officers' Mess Royston Road, Duxford, Cambridge, England, CB22 4QH.

  • GlobeNewswire

    Acacia Pharma Group plc: Notice of Annual General Meeting

    Cambridge, UK and Indianapolis, US – 16 March 2020 Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the.

  • GlobeNewswire

    Acacia Pharma Announces Brief Extension of FDA Review Period for NDA for BYFAVO™, an Ultra-short Acting and Reversible Anesthetic for Procedural Sedation

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 12 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (ACPH.NX), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for BYFAVO™ (remimazolam) by up to 90 days in order to complete its review of additional data submitted in January and February 2020.

  • GlobeNewswire

    Issue of Equity on Exercise of Options/Vesting of Performance Share Awards

    Cambridge, UK and Indianapolis, US – 9 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical.

  • GlobeNewswire

    Acacia Pharma Announces Changes to its Officers and Board of Directors

    Cambridge, UK and Indianapolis, US – 2 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (ACPH.NX), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the following changes to its Officers and Board of Directors. Christine Soden stepped down as a Director, as Chief Financial Officer and Company Secretary on 29 February 2020.

  • GlobeNewswire

    Acacia Pharma Group plc: Results for the year ended 31 December 2019

    Cambridge, UK and Indianapolis, US – 2 March 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (ACPH.NX), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces its results for the year ended 31 December 2019.

  • GlobeNewswire

    Acacia Pharma to Announce its Results for the Full Year 2019 on 2 March 2020 and Provides Notice of its Annual General Meeting

    Cambridge, UK and Indianapolis, US – 27 February 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused.

  • GlobeNewswire

    Acacia Pharma Announces US FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

    Cambridge, UK and Indianapolis, US – 27 February 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (ACPH.NX), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients. “The approval of our first product represents a significant milestone in Acacia Pharma’s evolution into an integrated hospital pharmaceutical company with strong development and commercialization capabilities,” commented Mike Bolinder, Acacia Pharma’s CEO.

  • GlobeNewswire

    Acacia Pharma wins BEL Small Company of the Year 2019

    Cambridge, UK and Indianapolis, US – 24 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the "Company”, the “Group”), (ACPH.NX), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company of the Year 2019 by Euronext Brussels at its annual New Year’s Ceremony held in Brussels last night.

  • GlobeNewswire

    TR-1: Standard form for notification of major holdings

    NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of.

  • GlobeNewswire

    Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals

    Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (the "Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and.

  • GlobeNewswire

    Acacia Pharma Group plc announces planned CFO succession

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the "Company”, the “Group”), (ACPH.NX), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces a planned succession of its Chief Financial Officer role. Christine Soden will step down as CFO and retire from the Board on 29 February 2020.

  • GlobeNewswire

    Acacia Pharma enters into strategic in-licensing, investment and loan transaction with Cosmo Pharmaceuticals N.V.

    Cambridge, UK and Indianapolis, US – 10 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (ACPH.NX), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces it has entered into a strategic in-licensing transaction with Cosmo Pharmaceuticals N.V. (SIX:COPN) (“Cosmo”). The transaction grants to the Group exclusive US commercialisation rights to ByFavo™ (remimazolam) and has been made alongside an equity investment and debt facility by Cosmo to finance the marketing efforts of both BARHEMSYS® and ByFavo.

  • GlobeNewswire

    PDMR Dealing/Issue of Equity

    Cambridge, UK and Indianapolis, US – 1 October 2019: Acacia Pharma Group plc (the "Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development.

  • GlobeNewswire

    Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 26 September 2019: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercializing hospital products for US and international markets, announces that the US Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for BARHEMSYS® (amisulpride injection).

  • GlobeNewswire

    Acacia Pharma Group plc - Issue of Equity on Exercise of Options/Vesting of Performance Share Awards

    Acacia Pharma Group plc Issue of Equity on Exercise of Options/Vesting of Performance Share Awards Cambridge, UK and Indianapolis, US – 16 September 2019: Acacia Pharma Group.